<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00976131</url>
  </required_header>
  <id_info>
    <org_study_id>AAAD8521</org_study_id>
    <nct_id>NCT00976131</nct_id>
  </id_info>
  <brief_title>Study of CoQ10 During One Cycle of Doxorubicin Treatment for Breast Cancer</brief_title>
  <official_title>Phase I Randomized, Placebo-Controlled, Cross-Over, Dose-Finding Pharmacokinetic Study of CoQ10 During One Cycle of Doxorubicin Treatment for Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heather Greenlee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study hopes to examine the effects of Coenzyme Q10 on doxorubicin (Adriamycin)&#xD;
      metabolism during breast cancer treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Doxorubicin is a lifesaving breast cancer treatment. However, approximately 3-20% of women&#xD;
      who receive doxorubicin treatment experience some damage to their heart muscle. Coenzyme Q10&#xD;
      is a fat soluble antioxidant dietary supplement that may protect against this heart damage&#xD;
      during doxorubicin treatment. It is unknown how Coenzyme Q10 may interact with doxorubicin.&#xD;
      This study will assess the effects of Coenzyme Q10 on doxorubicin metabolism.&#xD;
&#xD;
      This is a phase I randomized, placebo-controlled, cross-over pharmacokinetic and dose-finding&#xD;
      study to assess the safety of CoQ10 during doxorubicin treatment for breast cancer. Safety&#xD;
      will be assessed by measuring 1) intra-patient differences in doxorubicin and its active&#xD;
      metabolites, with and without CoQ10, and 2) adverse events. We hypothesize that CoQ10&#xD;
      administration during doxorubicin treatment is safe and will not affect doxorubicin active&#xD;
      metabolites. Using three dose levels of CoQ10, the maximum tolerated dose (MTD) will be&#xD;
      determined by assessing change in doxorubicin concentration (area under the curve (AUC),&#xD;
      change in peak concentration levels (Cmax)), and adverse events.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 2009</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of CoQ10 that does not alter the pharmacokinetics of doxorubicin</measure>
    <time_frame>Two weeks prior to cycles 3 and 4 of doxorubicin</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cycle 3 of doxorubicin with Coenzyme Q10, Cycle 4 with Coenzyme Q10 Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycle 3 of doxorubicin with Coenzyme Q10 Placebo, Cycle 4 with Coenzyme Q10</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Coenzyme Q10</intervention_name>
    <description>Dose Level 1:&#xD;
300mg/d (2 capsules) of CoQ10 taken daily for two weeks prior to Cycle 3 infusion of doxorubicin followed by 300mg/d placebo (2 capsules)taken daily for two weeks prior to Cycle 4 infusion of doxorubicin.&#xD;
Dose Level 2:&#xD;
600mg/d (4 capsules) of CoQ10 taken daily for two weeks prior to Cycle 3 infusion of doxorubicin followed by 600mg/d placebo (4 capsules) taken daily for two weeks prior to Cycle 4 infusion of doxorubicin.&#xD;
Dose Level 3:&#xD;
1200mg/d (8 capsules) of CoQ10 taken daily for two weeks prior to Cycle 3 infusion of doxorubicin followed by 1200mg/d placebo (8 capsules) taken daily for two weeks prior to Cycle 4 infusion of doxorubicin.</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>CoQ10</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Coenzyme Q10 Placebo</intervention_name>
    <description>Dose Level 1:&#xD;
300mg/d placebo (2 capsules) taken daily two weeks prior to Cycle 3 infusion of doxorubicin followed by 300mg/d (2 capsules) of CoQ10 taken daily two weeks prior to Cycle 4 infusion of doxorubicin.&#xD;
Dose Level 2:&#xD;
600mg/d placebo (4 capsules) taken daily two weeks prior to Cycle 3 infusion of doxorubicin followed by 600mg/d (4 capsules) of CoQ10 taken daily two weeks prior to Cycle 4 infusion of doxorubicin.&#xD;
Dose Level 3:&#xD;
1200mg/d placebo (8 capsules) taken daily two weeks prior to Cycle 3 infusion of doxorubicin followed by 1200mg/d (8 capsules) of CoQ10 taken daily two weeks prior to Cycle 4 infusion of doxorubicin.</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of early stage breast cancer (stage I, II, or III);&#xD;
&#xD;
          -  Scheduled to receive at least four rounds of dose dense doxorubicin therapy in the&#xD;
             neoadjuvant or adjuvant setting;&#xD;
&#xD;
          -  No other history of prior chemotherapy, radiation, or hormonal therapy in the previous&#xD;
             5 years;&#xD;
&#xD;
          -  For women receiving adjuvant therapy, single lumen implanted venous access device&#xD;
             (i.e. single port) for unilateral cancer and double lumen implanted venous access&#xD;
             device (i.e. double port) for bilateral breast cancer&#xD;
&#xD;
          -  Age 21 years or older;&#xD;
&#xD;
          -  ECOG performance status ≤ 2 (Karnofsky &gt; 60%);&#xD;
&#xD;
          -  Normal organ and marrow function defined as: Leukocytes ≥ 3,000/uL, Absolute&#xD;
             neutrophils count (ANC) ≥ 1,500/uL at baseline, Platelets ≥ 100,000/uL, Total&#xD;
             bilirubin ≤ 1.5 X normal institutional limits, AST (SGOT)/ALT (SGPT) ≤ 2.5 X&#xD;
             institutional ULN, Serum creatinine within normal institutional limits;&#xD;
&#xD;
          -  Left ventricular ejection fraction &gt; 55%;&#xD;
&#xD;
          -  No history of CoQ10 supplement use within 30 days of initiating study drug;&#xD;
&#xD;
          -  No uncontrolled or significant co-morbid illness;&#xD;
&#xD;
          -  Not pregnant, not breastfeeding, and not planning on becoming pregnant during the&#xD;
             course of the study;&#xD;
&#xD;
          -  Willingness to comply with all study intervention and follow-up procedures;&#xD;
&#xD;
          -  Ability to speak English or Spanish; and&#xD;
&#xD;
          -  Ability to provide informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to understand or an unwillingness to sign a written informed consent&#xD;
             document;&#xD;
&#xD;
          -  Any significant toxic side effects related to first or second dose of&#xD;
             doxorubicin/cyclophosphamide chemotherapy or biologic therapy that did not resolve to&#xD;
             less than a CTCAE 3.0 grade 3 non-hematological toxicity;&#xD;
&#xD;
          -  Currently using any investigational agent;&#xD;
&#xD;
          -  Unstable or severe intercurrent medical condition that, in the opinion of the&#xD;
             investigator, might interfere with the participant's ability to follow the protocol or&#xD;
             achieve study objectives;&#xD;
&#xD;
          -  Psychological or sociological conditions, addictive disorders, or family problems that&#xD;
             would preclude adherence with study drug or compliance with the protocol&#xD;
&#xD;
          -  Women who report pregnancy, are breast feeding, or have a positive pregnancy test;&#xD;
&#xD;
          -  Use of CoQ10 supplement use within 30 days of initiating study drug;&#xD;
&#xD;
          -  Use of over-the-counter nutritional vitamin greater than 5x RDA;&#xD;
&#xD;
          -  Fish allergy (due to fish-based softgel shell);&#xD;
&#xD;
          -  Currently taking FDA cardioprotective drugs, such as Zinecard (dexrazoxane);&#xD;
&#xD;
          -  History of chronic hepatitis B, hepatitis C, and HIV infection;&#xD;
&#xD;
          -  Problems swallowing oral medications due to prolonged emesis, mucositis, esophageal&#xD;
             dysfunction, etc.; and,&#xD;
&#xD;
          -  Currently taking any form of antioxidant supplements while on study.&#xD;
&#xD;
          -  Use of warfarin.&#xD;
&#xD;
          -  Kosher (due to fish-based softgel shell)&#xD;
&#xD;
          -  Dietary restriction of tilapia (due to tilapia fish-based softgel shell)&#xD;
&#xD;
          -  Titanium Dioxide allergy (due to the opaque coloring used in the softgel).&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heather Greenlee, ND, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <study_first_submitted>September 11, 2009</study_first_submitted>
  <study_first_submitted_qc>September 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2009</study_first_posted>
  <last_update_submitted>May 19, 2016</last_update_submitted>
  <last_update_submitted_qc>May 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Heather Greenlee</investigator_full_name>
    <investigator_title>Assistant Professor of Epidemiology</investigator_title>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Early Stage Breast Cancer</keyword>
  <keyword>Complementary and Alternative Medicine</keyword>
  <keyword>CAM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ubiquinone</mesh_term>
    <mesh_term>Coenzyme Q10</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

